StockNews.AI
APVO
StockNews.AI
119 days

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

1. Aptevo closed an offering of 2.32 million shares at $0.862 each. 2. Roth Capital Partners was the exclusive placement agent for the offering.

2m saved
Insight
Article

FAQ

Why Neutral?

The offering may stabilize funds but also dilute existing shares, balancing potential impacts.

How important is it?

The capital raised can support operations, but stock dilution may displease investors.

Why Short Term?

The immediate effects of stock offerings are usually felt in the short-term.

Related Companies

ROTH
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, announced the closing of its previously announced offering of 2,324,000 shares of the Company's common stock in a registered direct offering (the "offering") at a purchase price of $0.862 per share. Roth Capital Partners acted as the exclusive placement agent for the offering.

Related News